Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

NCT ID: NCT05918783

Last Updated: 2025-02-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-28
• Study Completion Date: 2028-12-30

Brief Summary

Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects.

Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure.

Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.

Detailed Description

A multicenter, open label, phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects.

Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Patients who are candidates for lung resection will be recruited as a diagnose and treat in the same anaesthesia, protocol; surgery will be performed at least 5 days and up to 21 days following the VTP procedure.

Study intervention will consist of robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer, an ablation mechanism with efficacy related to immune response post-ablation.

Conditions

Peripheral Lung Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A

will be a monotherapy light dose escalation with single dose of Padeliporfin at light laser doses of 150, 250 and 400 mW/cm for 20 minutes.

Part A will proceed with light dose escalation and will continue until the maximum tolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined.

Group Type: EXPERIMENTAL

Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Intervention Type: COMBINATION_PRODUCT

Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.

Part B

will be a dose expansion part at MTD/RP2D dose level identified in Part A to further assess the safety, tolerability, and treatment effect of the MTD and/ or RP2D

Group Type: EXPERIMENTAL

Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Intervention Type: COMBINATION_PRODUCT

Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.

Interventions

Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.

Intervention Type: COMBINATION_PRODUCT

Other Intervention Names

Padeliporfin VTP

Eligibility Criteria

Inclusion Criteria

1. Age ≥18

2. Patients with primary lung lesions who are at high risk for primary lung cancer.

2.1.Biopsy with intraoperative confirmation of malignancy using on-site cytology will be used as final inclusion prior to study treatment.

3. All patients will be approved by a multi-disciplinary team (thoracic surgery, interventional pulmonology, medical oncology and radiation oncology) as appropriate for bronchoscopic VTP prior to surgical resection.

4. Tumor size targeted for VTP treatment ≤ 2 cm (Part A) and <3cm (Part B), based on CT scan, including solid or semi-solid tumors.

5. EBUS mediastinal staging performed intraoperative prior to VTP treatment with rapid on-site evaluation negative for nodal involvement of malignancy.

6. Tumor is ≥ 2cm from the central bronchial tree (distal 2 cm of the trachea, carina, and named major lobar bronchi up to their first bifurcation) (Timmerman, 2018).

7. Lung lesion is not contiguous with and ≥ 1 cm from the pleura/fissures.

8. Patient is eligible to undergo bronchoscopy under general anesthesia.

9. Tumor is accessible for Padeliporfin VTP treatment via robotic bronchoscopy

10. ECOG performance score 0-2

11. Estimated life expectancy of ≥3 months

12. Adequate organ system function

13. Negative serum pregnancy test

Exclusion Criteria

1. Patient has a centrally located lung lesion, as defined by RTOG within 2 cm of the proximal bronchial tree, or within 2 cm of other major mediastinal structure (aorta, heart, trachea, pericardium, superior vena cava, pulmonary artery, esophagus, vertebra's body or spinal canal).

2. Patient has a lung lesion located less than 1 cm from the pleura or fissure

3. Patient has a lung cancer lesion >2cm in diameter, for the expansion cohort lesion >2-3 cm

4. Patient has cytologic or histologic evidence of nodal disease

5. Tumor invades major vessels

6. Prior exposure to VTP or PDT treatments

7. Pregnant or breastfeeding women

8. Receiving any other investigational treatment

9. Co-morbidities:

1. Baseline hypoxia with O2 saturation <92% on 2L NC or more of oxygen

2. New York Heart Association (NYHA) stage III/IV heart failure

3. Unstable coronary artery disease or MI within the last 6 months

4. Uncontrollable clinically serious arrhythmia

5. Decompensated/clinically worsening interstitial lung disease or obstructive lung disease.

6. Unstable cerebrovascular or peripheral vascular disease

7. Inability to stop anticoagulation or anti-platelet therapy peri-procedure

8. Evidence of clinically active infection requiring systemic (any route) antibiotic therapy. All prior infections must have resolved following optimal therapy.

9. Patient has any acute or chronic condition assessed as clinically significant by Investigator which may preclude bronchoscopy procedure

10. History of medical or psychiatric disease which, in the view of the investigator, would preclude safe treatment or acceptable study compliance

11. Known severe pulmonary hypertension (mean pulmonary arterial pressure ≥ 50 mmHg)

10. Patient has a cancer diagnosis with active disease requiring further cancer therapy.

11. Patient has had major surgery within the last 4 weeks.

12. Patient has porphyria or hypersensitivity to padeliporfin or porphyrin-like compounds or to any of its excipients.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Impact Biotech Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lonny Yarmus, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Eyal Morag, MD

Role: CONTACT

eyal.morag@impactbiotech.com

+972542056619

Facility Contacts

Lonny Yarmus

Role: primary

Other Identifiers

CLIN2201 LCM101

Identifier Type: -

Identifier Source: org_study_id